Subscribe To
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive kva12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial...
November 3, 2023, 8:01 pm
Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023
SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immu...
October 9, 2023, 4:10 pm
Kineta to present preclinical data on vista blocking kva12123 at immuno us 2023
SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immun...
October 9, 2023, 12:10 pm
Kineta reports second quarter 2023 financial results and provides corporate update
Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting kva12123 in Advanced Soli...
August 11, 2023, 8:01 pm
Kineta to host key opinion leader event on kva12123: vista as an immuno-oncology target
SEATTLE, March 06, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation i...
March 6, 2023, 11:30 am